OrbiMed Advisors GERN Position
Exited7-Fund ConvergenceOrbiMed Advisors exited their position in Geron Corporation (GERN) in Q3 2024, after holding the stock for 4 quarters.
The position was first reported in Q4 2023 and has been tracked across 4 quarterly 13F filings.
GERN is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Imetelstat in 806 days (Jun 30, 2028), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 10.3% of float with 3.2 days to cover, indicating significant bearish positioning against the stock.
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Full company profile →Short Interest
10.3%
3.2 days to cover
OrbiMed Advisors GERN Position History
Frequently Asked Questions
Does OrbiMed Advisors own GERN?
No. OrbiMed Advisors exited their position in Geron Corporation (GERN) in Q3 2024. They previously held the stock for 4 quarters.
How many hedge funds own GERN?
7 specialist biotech hedge funds currently hold GERN, including RTW Investments, RA Capital Management, Deep Track Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy GERN?
OrbiMed Advisors's position in GERN was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's GERN position increasing or decreasing?
OrbiMed Advisors completely exited their GERN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GERNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →